摘要
目的观察昆明山海棠(THH)提取物在急性移植物抗宿主病(aGVHD)中的作用及其可能的作用机制。方法建立aGVHD模型,BALB/c受鼠清髓性预处理后分别用生理盐水、环孢素A(CsA)、THH及CsA+THH混合物灌胃。观察移植后受鼠aGVHD、生存时间、CD4+/CD8+比率、CD4+CD25+T细胞比率及脾细胞Foxp3 mRNA水平。结果生理盐水组出现典型aGVHD,20天内全部死亡。其余3组aGVHD临床、病理表现及生存时间均改善,组间无差异;CD4+/CD8+比率、受鼠CD4+CD25+T细胞比率及脾Foxp3 mRNA表达较生理盐水组升高,以联用组明显。结论THH可减轻小鼠aGVHD,延长其生存时间。机制可能与增加CD4+CD25+T细胞比率,上调Foxp3 mRNA表达,调节CD4+/CD8+比率有关。THH和小剂量CsA联合有协同作用。
Objective To observe the prophylactic effect of Tripterygium hypoglaucum Hutch(THH) extract on acute graft-versus-host disease(aGVHD) in mice following hematopoietic stem cell transplantation(HSCT).Methods 1×10^8 bone marrow cells mixed with 1×10^8 spleen cells from C57BL/6 mice were transplanted into the death irradiated BABL/c mice to establish the aGVHD model.Recipient mice were treated with 0.9% sodium chloride(group A),ciclosporin A(group B),THH extract(group C) and THH combined with CsA(group D).The signs of clinical aGVHD,histological evidence of aGVHD were assessed by survival,CD4^+ and CD8+ T cell subsets,CD4^+CD25^+ subpopulation and the expression of Foxp3 in splenocytes after HSCT.Results The medium survival time for group A was 9 days and within 20 days after HSCT,all mice died,while that in groups B,C and D was over 30 days,which was significantly longer than in group A(P〈0.05).Group A mice exhibited significant clinical symptoms and histological signs of aGVHD,whereas those of groups B,C and D showed only mild clinical and histological signs of aGVHD.The ratio of CD4^+ T cells/CD8^+ T cells,percentage of CD4^+CD25^+ T cells and the level of Foxp3 in the spleen in groups B,C and D were higher than group A,and group D showed the maximum effect.Conclusion THH can prevent aGVHD after allogeneic bone marrow transplantation in mice.The possible mechanism is involved in the upregulation of Foxp3 expression to induce CD4^+CD25^+ regulatory T cells and the regulation of the CD4^+ and CD8^+ T cells.THH combined with CsA showed synergic effect in the prevention of aGVHD.
出处
《徐州医学院学报》
CAS
2010年第4期211-214,共4页
Acta Academiae Medicinae Xuzhou
基金
国家自然科学基金(30170389)
江苏省中医药管理局项目(H05104)